Cancer diagnosis and imaging
AssigneeTau Therapeutics LLC
InventorLloyd S. Gray
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for imaging a disease or condition in a mammal which includes the steps of; administering a therapeutically effective amount of a cell cycle inhibitor to effectively stop proliferation of eukaryotic cells at a cell cycle checkpoint between the G1 and S phase, stopping administration of the cell cycle inhibitor for a period of time, administering a marker to the mammal and imaging the mammal.
Claims21
A method for increasing the sensitivity of imaging a cancerous or pre-cancerous disease in a mammal which comprises the steps of:
- (a) administering to the mammal an effective amount of a T-type calcium channel inhibitor that inhibits proliferation of cancerous or pre-cancerous diseased cells by inhibiting cell cycle progression through the checkpoint between the G1 and S phase wherein the diseased cells accumulate at the G1/S checkpoint of the cell cycle;
- (b) subsequently administering an imaging marker to the mammal after a period wherein cells that have accumulated at the G1/S checkpoint of the cell cycle following administration of the T-type calcium channel inhibitor have progressed to the S phase of the cell cycle, resulting in an increased proportion of the diseased cells in the S phase of the cell cycle;
- and (c) imaging the mammal with an imager and obtaining an image of diseased cells with greater sensitivity compared with imaging in the absence of administration of the T-type calcium channel inhibitor.
A method for increasing the sensitivity of imaging a cancer in a human which comprises the steps of:
- (a) administering to the human an effective amount of mibefradil that inhibits proliferation of cancer cells by inhibiting cell cycle progression through the checkpoint between the G1 and S phase wherein the cancer cells accumulate at the G1/S checkpoint of the cell cycle;
- (b) subsequently administering an imaging marker to the human after a period wherein cells that have accumulated at the G1/S checkpoint of the cell cycle following administration of the T-type calcium channel inhibitor have progressed to the S phase of the cell cycle, resulting in an increased proportion of the diseased cells in the S phase of the cell cycle;
- and
- (c) imaging the human with an imager and obtaining an image of cancer cells with greater sensitivity compared with imaging in the absence of administration of the mibefradil.
Dependencies are inferred from the claim text.